Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Fusion Pharmaceuticals

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Chronic Myeloid Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Treatments: Drug: PF-114

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02885766

PF-114-01

Details and patient eligibility

About

A multicenter, open label cohort Phase 1 dose finding study to evaluate tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 for oral administration in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), which is resistant to the 2-nd generation Bcr-Abl inhibitors or has T315I mutation in the BCR-ABL gene.

Full description

PF-114 is a low molecular inhibitor of a Bcr-Abl kinase activity, which is active with respect to native and mutated forms of this enzyme with mutations in Abl kinase domain. Preclinical in vitro and in vivo studies have demonstrated the ability of PF-114 to inhibit wild Bcr-Abl type and with T315I mutation, as well as other kinds of Bcr-Abl with mutations in kinase domain, including combined mutations.

In contrast to ponatinib, PF-114 is being developed to increase the action selectivity with respect to Bcr-Abl, which potentially should increase safety of drug application in people. The results of performed preclinical studies confirmed improved selectivity of PF-114 action with respect to Bcr-Abl kinases as compared to ponatinib.

Indication:

Adult patients with Ph+ CML in chronic phase (CP) or accelerated phase (AP) resistant to previous treatment with at least one 2-nd generation inhibitor of Bcr-Abl (dasatinib, nilotinib, bosutinib) or intolerant of approved Bcr-Abl inhibitors or with T315I mutation in the BCR-ABL gene

Enrollment: 65 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients must meet all of the following criteria in order to be eligible for participation in the study:

1. Able to give written informed consent;

2. Male or female patient ≥ 18 years old;

3. Confirmed diagnosis of CML in chronic or accelerated phase according to European LeukemiaNet guideline as of 2013;

4. Available information regarding resistance to the therapy with least one 2-nd generation Bcr-Abl inhibitor (dasatinib or nilotinib or bosutinib), or intolerance of approved Bcr-Abl inhibitors, or presence of T315I mutation irrespective of treatment history;

5. In case of previous history of blast crisis phase of CML at least 6 months are required to pass after the end of blast crisis phase before the first dose of PF-114;

6. ECOG performance status ≤ 2 (see Appendix 2);

7. Adequate renal function defined as serum creatinine ≤ 1.5 times upper limit of normal (ULN);

8. Adequate hepatic function defied as:

   • serum bilirubin ≤ 1.5 X ULN unless a patient is diagnosed with Gilbert's syndrome;
   • serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X ULN;
   • alkaline phosphatase ≤ 2.5 X ULN;
   • INR ≤ 1.5 X ULN;

9. Adequate cardiac function defined as LVEF > 40 % by echocardiogram;

10. QTcF < 470 ms;

11. Patient has recovered (to Grade 1 or less according to NCI CTCAE V 4.0) from toxicities (excluding alopecia) associated with any prior treatments;

12. Female patients of childbearing potential and male patients who have female partners of childbearing potential must agree with abstinence from sexual relations or use effective methods of contraception throughout participation in the study;

13. Ability to comply with study procedures in the Investigator's opinion.

Exclusion criteria

Patients must not meet any of the following criteria in order to be eligible for participation in the study:

1. Use of the following previous therapy:

   1. chemotherapy ≤ 21 days (except hydroxyurea for which washout is not required) prior to the first dose of PF-114 mesylate; оr nitrosoureas оr mitomycin С ≤ 42 days prior to the first dose of PF-114 mesylate;
   2. approved tyrosine kinase inhibitors or investigational agents ≤ 4 days prior to the first dose of PF-114;
   3. radiotherapy ≤ 28 days prior to the first dose of PF-114 ;
   4. autologous оr allogeneic stem сеll transplant < 90 days prior to enrollment;

2. Significant uncontrolled cardiac disease;

3. Sustained uncontrolled hypertension ≥ Grade 2 (according to NCI CTC AE v4);

4. Patient is taking medicinal products known to prolong the QT interval on the electrocardiogram, unless they are absolutely necessary in the opinion of the investigator;

5. Evidence of on-going graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy. Patients should be off immunosuppressive therapy for prophylaxis and/or treatment for at least 14 days prior to the first dose of PF-114;

6. Major surgery within 35 days prior to enrollment;

7. Uncontrolled intercurrent illness including, but not limited to the following: active systemic infection, uncontrolled seizure disorder, psychiatric or social circumstances that would limit compliance with study requirements or misrepresent results of the study;

8. Patient is unable to swallow study drug or has gastro-intestinal disorders that could negatively affect oral absorption of PF-114 ;

9. Any malignancy other than CML within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ).

10. Pregnancy or breast feeding.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

65 participants in 1 patient group

PF-114

Experimental group

Description:

PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied. When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor. Orally, once daily

Treatment:

Drug: PF-114